Advertisement
ALNY or ARGNF or ARGX
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. argenx SE (ARGNF) vs. argenx SE (ARGX) Stock Comparison
Key Takeaways
- Alnylam Pharmaceuticals (ALNY) outperforms year-to-date (YTD) with a 25.54% return, fueled by robust first-quarter 2026 sales of its flagship drug Amvuttra.
- argenx SE's NASDAQ American Depositary Receipt (ARGX) delivers a 20.60% one-year gain, while its OTC listing (ARGNF) lags at 3.89% over the same period.
- All three stocks hail from the biotechnology sector, with ALNY focused on RNA interference (RNAi; a technology silencing disease-causing genes) and argenx on antibody therapies for autoimmune diseases.
- Recent catalysts include ALNY's earnings beat and argenx's positive clinical data presented at the 2026 American Academy of Neurology (AAN) meeting.
- Market caps cluster around $40-50 billion, with ALNY at $39.5 billion, ARGX at $49 billion, and ARGNF at $47.5 billion.
- ALNY trades at a higher trailing price-to-earnings (P/E) ratio of 74 versus argenx's approximately 38-40, reflecting growth expectations.
Introduction
This stock comparison examines ALNY, ARGNF, and ARGX, three biotechnology players navigating innovative therapies in genetic and autoimmune diseases. Alnylam Pharmaceuticals leads in RNAi-based treatments, while argenx SE's dual listings offer exposure to antibody platforms targeting neuromuscular and immune disorders. Traders and investors focused on biotech growth stocks may find value in assessing their relative performance amid recent earnings reports, clinical updates, and market momentum. This analysis highlights key metrics and developments to inform portfolio positioning in a volatile sector.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals (ALNY) is a leader in RNAi therapeutics, developing drugs that silence faulty genes to treat rare diseases like hereditary transthyretin-mediated (hATTR) amyloidosis and primary hyperoxaluria. In recent market activity, the stock has shown resilience with a YTD gain of 25.54% despite trading around $296, within a 52-week range of $246-$496. Sentiment has been bolstered by first-quarter 2026 results, where revenue hit $1.17 billion—beating estimates—driven by nearly $890 million in Amvuttra sales, up significantly year-over-year. This commercial momentum, alongside a robust pipeline in Phase 3 trials, has supported upward trends, though biotech volatility tempers gains.
ARGNF Overview and Recent Performance
argenx SE (ARGNF), traded on OTC markets, develops antibody-based therapies for severe autoimmune conditions, including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) via its lead product Vyvgart. The stock trades near $725, with a 52-week range of $532-$895 and a YTD return of 16.72%. Recent weeks feature anticipation for first-quarter 2026 earnings on May 7, following strong prior-quarter revenue of $1.12 billion. Positive pipeline progress, including expansions for Vyvgart, influences steady sentiment, though OTC liquidity can amplify price swings relative to its NASDAQ counterpart.
ARGX Overview and Recent Performance
argenx SE's NASDAQ ADR (ARGX) mirrors the OTC listing's focus on immunology, with Vyvgart approved for gMG and immune thrombocytopenia (ITP). Priced around $784 in a 52-week range of $510-$935, it has posted a one-year return of 20.60% but modest YTD growth of 6.49%. Recent performance reflects optimism from new Vyvgart data at the 2026 AAN meeting, supporting broader applications in neuromuscular diseases, ahead of Q1 results. This has sustained market interest amid sector headwinds.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the platform's top 25 AI-powered trading bots out of 351 available, each scanning thousands of tickers for real-time signals across stocks, ETFs, and crypto. These bots employ machine learning strategies like signal agents and virtual portfolios, delivering stats such as annualized returns up to +163%, win rates of 59-75%, profit factors around 1.75-3.33, and profit-to-drawdown ratios exceeding 8. Examples include semiconductor-focused bots with +84-97% returns and 63-68% win rates. With diverse styles—from short-term volatility plays to sector momentum—Tickeron's hundreds of bots adapt to market conditions. Explore the curated list to identify high-performing options suited to current trends.
Head-to-Head Comparison
ALNY differentiates through its RNAi platform targeting genetic root causes, contrasting argenx's (ARGNF and ARGX) neonatal Fc receptor (FcRn) antibodies that reduce harmful autoantibodies. Growth drivers align on commercial blockbusters—Amvuttra for ALNY, Vyvgart for argenx—with similar trailing-12-month revenues near $4.25 billion. Recent momentum favors ALNY's post-earnings stability over argenx's pre-earnings positioning. Risks include clinical trial outcomes and competition for all, with biotech sector exposure amplifying volatility. Valuation sensitivity shows ALNY's elevated P/E (74 trailing) versus argenx's mid-30s, signaling higher growth pricing. Market sentiment tilts positive on ALNY's sales surge and argenx's data readouts, with ADR (ARGX) offering better liquidity than OTC (ARGNF).
Tickeron AI Verdict
Tickeron's AI models currently lean toward ALNY based on superior YTD trend consistency, a recent earnings catalyst with Amvuttra momentum, and stronger relative positioning in recent market activity. argenx listings (ARGNF, ARGX) present compelling pipeline upside ahead of earnings, but ALNY edges out on observable stability and performance metrics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileARGNF’s FA Score has 1 green FA rating(s), and ARGX’s FA Score reflects 1 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- ARGNF’s FA Score: 1 green, 4 red.
- ARGX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 3 TA indicator(s) are bullish while ARGNF’s TA Score has 3 bullish TA indicator(s), and ARGX’s TA Score reflects 5 bullish TA indicator(s).
- ALNY’s TA Score: 3 bullish, 6 bearish.
- ARGNF’s TA Score: 3 bullish, 3 bearish.
- ARGX’s TA Score: 5 bullish, 5 bearish.
Price Growth
ALNY (@Biotechnology) experienced а -3.02% price change this week, while ARGNF (@Biotechnology) price change was 0.00% , and ARGX (@Biotechnology) price fluctuated +2.29% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.42%. For the same industry, the average monthly price growth was +2.95%, and the average quarterly price growth was +10.88%.
Reported Earning Dates
ALNY is expected to report earnings on Jul 30, 2026.
ARGX is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Biotechnology (-2.42% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ALNY | ARGNF | ARGX | |
| Capitalization | 39B | 50.6B | 50.6B |
| EBITDA | 866M | 1.51B | 1.51B |
| Gain YTD | -26.561 | -7.679 | -3.336 |
| P/E Ratio | 73.37 | 35.68 | 36.11 |
| Revenue | 4.29B | 4.66B | 4.66B |
| Total Cash | 3.01B | 3.93B | 3.93B |
| Total Debt | 1.27B | 43.2M | 43.2M |
ALNY | ARGNF | ARGX | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 94 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 81 Overvalued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 58 | 12 | 24 | |
SMR RATING 1..100 | 14 | 39 | 39 | |
PRICE GROWTH RATING 1..100 | 64 | 47 | 51 | |
P/E GROWTH RATING 1..100 | 100 | 46 | 39 | |
SEASONALITY SCORE 1..100 | 85 | 1 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARGNF's Valuation (81) in the null industry is in the same range as ARGX (82) in the Pharmaceuticals Other industry, and is in the same range as ALNY (89) in the Biotechnology industry. This means that ARGNF's stock grew similarly to ARGX’s and similarly to ALNY’s over the last 12 months.
ARGNF's Profit vs Risk Rating (12) in the null industry is in the same range as ARGX (24) in the Pharmaceuticals Other industry, and is somewhat better than the same rating for ALNY (58) in the Biotechnology industry. This means that ARGNF's stock grew similarly to ARGX’s and somewhat faster than ALNY’s over the last 12 months.
ALNY's SMR Rating (14) in the Biotechnology industry is in the same range as ARGNF (39) in the null industry, and is in the same range as ARGX (39) in the Pharmaceuticals Other industry. This means that ALNY's stock grew similarly to ARGNF’s and similarly to ARGX’s over the last 12 months.
ARGNF's Price Growth Rating (47) in the null industry is in the same range as ARGX (51) in the Pharmaceuticals Other industry, and is in the same range as ALNY (64) in the Biotechnology industry. This means that ARGNF's stock grew similarly to ARGX’s and similarly to ALNY’s over the last 12 months.
ARGX's P/E Growth Rating (39) in the Pharmaceuticals Other industry is in the same range as ARGNF (46) in the null industry, and is somewhat better than the same rating for ALNY (100) in the Biotechnology industry. This means that ARGX's stock grew similarly to ARGNF’s and somewhat faster than ALNY’s over the last 12 months.
| ALNY | ARGNF | ARGX | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 14% | 1 day ago 42% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 31% | 1 day ago 58% |
| Momentum ODDS (%) | 1 day ago 74% | 1 day ago 40% | 1 day ago 70% |
| MACD ODDS (%) | 1 day ago 76% | 1 day ago 50% | 1 day ago 54% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 32% | 1 day ago 68% |
| TrendMonth ODDS (%) | 1 day ago 70% | 1 day ago 31% | 1 day ago 65% |
| Advances ODDS (%) | 8 days ago 76% | N/A | 10 days ago 71% |
| Declines ODDS (%) | 3 days ago 66% | N/A | 6 days ago 64% |
| BollingerBands ODDS (%) | 1 day ago 82% | 1 day ago 20% | N/A |
| Aroon ODDS (%) | 1 day ago 72% | N/A | 1 day ago 73% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| UFT.X | 0.002054 | N/A | N/A |
| UniLend cryptocurrency | |||
| ALGO.X | 0.122111 | -0.000943 | -0.77% |
| Algorand cryptocurrency | |||
| MINA.X | 0.066464 | -0.001479 | -2.18% |
| Mina cryptocurrency | |||
| ALPINE.X | 0.482653 | -0.017080 | -3.42% |
| Alpine F1 Team Fan Token cryptocurrency | |||
| WAXP.X | 0.006926 | -0.000339 | -4.67% |
| WAX cryptocurrency | |||
ALNY and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with ARGX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then ARGX could also see price increases.
| Ticker / NAME | Correlation To ALNY | 1D Price Change % | ||
|---|---|---|---|---|
| ALNY | 100% | +2.52% | ||
| ARGX - ALNY | 50% Loosely correlated | -0.05% | ||
| UTHR - ALNY | 35% Loosely correlated | +2.08% | ||
| AXON - ALNY | 35% Loosely correlated | -0.18% | ||
| BCRX - ALNY | 33% Loosely correlated | +2.56% | ||
| RARE - ALNY | 32% Poorly correlated | +2.05% | ||
More | ||||
ARGNF and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARGNF has been loosely correlated with ARGX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGNF jumps, then ARGX could also see price increases.
| Ticker / NAME | Correlation To ARGNF | 1D Price Change % | ||
|---|---|---|---|---|
| ARGNF | 100% | N/A | ||
| ARGX - ARGNF | 54% Loosely correlated | -0.05% | ||
| MNKD - ARGNF | 30% Poorly correlated | -2.38% | ||
| TNXP - ARGNF | 25% Poorly correlated | -5.88% | ||
| ROIV - ARGNF | 24% Poorly correlated | +1.52% | ||
| IMVT - ARGNF | 24% Poorly correlated | -1.41% | ||
More | ||||